Combination treatment with mirabegron and solifenacin in patients with overactive bladder: Efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (symphony)

European Urology

Volumn 67, Issue 3, 2015, Pages 577-588

  Abrams, Paul ^a   Kelleher, Con ^b   Staskin, David ^c   Rechberger, Tomasz ^d   Kay, Richard ^e   Martina, Reynaldo ^f   Newgreen, Donald ^f   Paireddy, Asha ^f   Van Maanen, Rob ^f   Ridder, Arwin ^f  

^a SOUTHMEAD HOSPITAL   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^e RK Statistics Ltd   (United Kingdom)

^f Astellas Pharma Global Development   (Netherlands)

Author keywords

Combination therapy; Mirabegron; Overactive bladder; Solifenacin

Indexed keywords

MIRABEGRON; PLACEBO; SOLIFENACIN; ACETANILIDE DERIVATIVE; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; DRUG COMBINATION; MUSCARINIC RECEPTOR BLOCKING AGENT; THIAZOLE DERIVATIVE; URINARY TRACT AGENT;

ADULT; ARTICLE; BLURRED VISION; CONFUSION; CONSTIPATION; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FATIGUE; FEMALE; FOLLOW UP; FREQUENCY URGENCY WITHOUT INCONTINENCE; HEADACHE; HUMAN; HYPERTENSION; INFLUENZA; MAJOR CLINICAL STUDY; MALE; MIXED STRESS URGENCY INCONTINENCE; MONOTHERAPY; MULTICENTER STUDY; OVERACTIVE BLADDER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; TABLET; TACHYCARDIA; TREATMENT DURATION; URGENCY INCONTINENCE; URINARY FREQUENCY; URINARY TRACT INFECTION; URINE RETENTION; XEROSTOMIA; AGED; BLADDER; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG COMBINATION; DRUG EFFECTS; EUROPE; MICTURITION; MIDDLE AGED; PATHOPHYSIOLOGY; TIME; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; URODYNAMICS;

ACETANILIDES; ADRENERGIC BETA-3 RECEPTOR AGONISTS; ADULT; AGED; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; EUROPE; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; SOLIFENACIN SUCCINATE; THIAZOLES; TIME FACTORS; TREATMENT OUTCOME; URINARY BLADDER; URINARY BLADDER, OVERACTIVE; URINATION; URODYNAMICS; UROLOGICAL AGENTS;

EID: 84922243411     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2014.02.012     Document Type: Article

References (17)

1. J.S. Benner, M.B. Nichol, and E.S. Rovner Patient-reported reasons for discontinuing overactive bladder medication BJU Int 105 2010 1276 1282
2. V. Khullar, G. Amarenco, and J.C. Angulo Efficacy and tolerability of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial Eur Urol 63 2013 283 295
3. V.W. Nitti, S. Auerbach, and N. Martin Results of a randomized phase III trial of mirabegron in patients with overactive bladder J Urol 189 2013 1388 1395
4. S. Herschorn, J. Barkin, and D. Castro-Diaz A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β3-adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder Urology 82 2013 313 320
5. Korstanje C, Someya A, Yanai H, et al. Additive effects for increased bladder storage function with the antimuscarinic drug solifenacin and the selective β3-adrenoceptor agonist mirabegron in two rat models for in vivo bladder function. Poster 81 presented at: 43rd Meeting of the International Continence Society; August 26-30, 2013; Barcelona, Spain.
6. J.G. Blaivas, G. Panagopoulos, J.P. Weiss, C. Somaroo, and D.C. Chaikin The urgency perception score: validation and test-retest J Urol 177 2007 199 202
7. P. Abrams, and S. Swift Solifenacin is effective for the treatment of OAB dry patients: a pooled analysis Eur Urol 48 2005 483 487
8. C. Chapple, V. Dvorak, and P. Radziszewski A phase II dose-ranging study of mirabegron in patients with overactive bladder Int Urogynecol J 24 2013 1447 1458
9. R.H. Myers, D.C. Montgomery, and C.M. Anderson-Cook Response surface methodology: process and product optimization using designed experiments ed. 3. 2009 Wiley Hoboken, NJ p. 704
10. S.-M. Hsiao, C.F. Hsiao, C.H. Chen, T.C. Chang, W.Y. Wu, and H.H. Lin Evaluation of bladder diary parameters based on correlation with the volume at strong desire to void in filling cystometry PloS ONE 8 2013 e69946
11. C.R. Chapple, L. Cardozo, W.D. Steers, and F.E. Govier Solifenacin significantly improves all symptoms of overactive bladder syndrome Int J Clin Pract 60 2006 959 966
12. A. Mangera, C.R. Chapple, Z.S. Kopp, and M. Plested The placebo effect in overactive bladder syndrome Nat Rev Urol 8 2011 495 503
13. W.J.J. Krauwinkel, V.M. Kerbusch, J. Meijer, R. Tretter, G. Strabach, and E.M. van Gelderen Evaluation of the pharmacokinetic interaction between the β3-adrenoceptor agonist mirabegron and the muscarinic receptor antagonist solifenacin in healthy subjects Clin Pharm Drug Dev 2 2013 255 263
14. S.H. Lee, S.S. Byun, S.J. Lee, K.H. Kim, and J.Y. Lee Effects of initial combined tamsulosin and solifenacin therapy for overactive bladder and bladder outlet obstruction secondary to benign prostatic hyperplasia: a prospective, randomized, multicenter study Int Urol Nephrol 46 2014 523 529
15. S.A. Kaplan, W. He, W.D. Koltun, J. Cummings, T. Schneider, and A. Fakhoury Solifenacin plus tamsulosin combination treatment in men with lower urinary tract symptoms and bladder outlet obstruction: a randomized controlled trial Eur Urol 63 2013 158 165
16. O. Yamaguchi, H. Kakizaki, and Y. Homma Solifenacin as add-on therapy for overactive bladder symptoms in men treated for lower urinary tract symptoms - ASSIST, randomized controlled study Urology 78 2011 126 133
17. S.H. Lee, M.S. Choo, and D.Y. Kim Combination treatment with propiverine hydrochloride plus doxazosin controlled release gastrointestinal therapeutic system formulation for overactive bladder and coexisting benign prostatic obstruction: a prospective, randomized, controlled multicenter study J Urol 174 2005 1334 1338